MA39211A1 - Composés tricycliques comme agents anti-cancers - Google Patents

Composés tricycliques comme agents anti-cancers

Info

Publication number
MA39211A1
MA39211A1 MA39211A MA39211A MA39211A1 MA 39211 A1 MA39211 A1 MA 39211A1 MA 39211 A MA39211 A MA 39211A MA 39211 A MA39211 A MA 39211A MA 39211 A1 MA39211 A1 MA 39211A1
Authority
MA
Morocco
Prior art keywords
tricyclic compounds
cancer agents
compounds
tricyclic
treatment
Prior art date
Application number
MA39211A
Other languages
English (en)
Other versions
MA39211B1 (fr
Inventor
Ashvinikumar V Gavai
George V Delucca
Daniel O'malley
Patrice Gill
Claude A Quesnelle
Francis Y Lee
John S Tokarski
Derek J Norris
Wayne Vaccaro
Mikkel V Debenedetto
Andrew P Degnan
Haiquan Fang
Matthew D Hill
Hong Huang
William D Schmitz
John E Starrett
Wen-Ching Han
Sunil Kumar Mandal
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA39211A1 publication Critical patent/MA39211A1/fr
Publication of MA39211B1 publication Critical patent/MA39211B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne des composés tricycliques (i), des compositions pharmaceutiquement acceptables contenant des composés de l'invention et des procédés d'utilisation desdites compositions dans le traitement de divers troubles.
MA39211A 2013-12-24 2014-12-23 Composés tricycliques comme agents anti-cancers MA39211B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361920500P 2013-12-24 2013-12-24
PCT/US2014/072031 WO2015100282A1 (fr) 2013-12-24 2014-12-23 Composés tricycliques comme agents anti-cancers

Publications (2)

Publication Number Publication Date
MA39211A1 true MA39211A1 (fr) 2018-08-31
MA39211B1 MA39211B1 (fr) 2019-01-31

Family

ID=52293305

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39211A MA39211B1 (fr) 2013-12-24 2014-12-23 Composés tricycliques comme agents anti-cancers

Country Status (34)

Country Link
US (1) US20160318928A1 (fr)
EP (2) EP3087071B1 (fr)
JP (2) JP6466456B2 (fr)
KR (1) KR102457145B1 (fr)
CN (2) CN108558871B (fr)
AR (2) AR099379A1 (fr)
AU (1) AU2014369982B2 (fr)
BR (1) BR112016013744B1 (fr)
CA (1) CA2934953C (fr)
CL (1) CL2016001629A1 (fr)
CY (2) CY1121076T1 (fr)
DK (2) DK3466949T3 (fr)
EA (2) EA032469B1 (fr)
ES (2) ES2698998T3 (fr)
HR (2) HRP20181849T1 (fr)
HU (2) HUE041719T2 (fr)
IL (1) IL246359B (fr)
LT (2) LT3466949T (fr)
MA (1) MA39211B1 (fr)
MX (1) MX369491B (fr)
MY (1) MY176489A (fr)
NZ (1) NZ722326A (fr)
PE (1) PE20160844A1 (fr)
PH (1) PH12016500953A1 (fr)
PL (2) PL3466949T3 (fr)
PT (2) PT3466949T (fr)
RS (2) RS58014B1 (fr)
SG (1) SG11201605097SA (fr)
SI (2) SI3466949T1 (fr)
SM (2) SMT202100165T1 (fr)
TN (1) TN2016000238A1 (fr)
TW (2) TWI726544B (fr)
UY (1) UY35916A (fr)
WO (1) WO2015100282A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2961747B1 (fr) 2013-02-27 2017-11-15 Bristol-Myers Squibb Company Composés de carbazole utiles en tant qu'inhibiteurs de bromodomaine
RU2016122654A (ru) 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
KR102457145B1 (ko) * 2013-12-24 2022-10-19 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 트리시클릭 화합물
WO2015131005A1 (fr) * 2014-02-28 2015-09-03 The Regents Of The University Of Michigan 9h-pyrimido[4,5-b]indoles et leurs analogues associés comme inhibiteurs de bromodomaine bet
ES2770349T3 (es) 2015-05-12 2020-07-01 Bristol Myers Squibb Co Compuestos de 5H-pirido[3,2-b]indol como agentes antineoplásicos
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
CA2991628C (fr) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. Nouvelle approche pour le traitement du cancer par immunomodulation
EP3355922A2 (fr) * 2015-10-02 2018-08-08 Dana Farber Cancer Institute, Inc. Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle
WO2017124934A1 (fr) * 2016-01-20 2017-07-27 宁波文达医药科技有限公司 Dérivé de carboline contenant de la phosphine servant d'inhibiteur de bromodomaine
CN108137589B (zh) * 2016-01-20 2021-03-26 宁波文达医药科技有限公司 作为布罗莫区结构域抑制剂的咔啉衍生物
US20190040063A1 (en) * 2016-02-05 2019-02-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compound for bromodomain-containing protein inhibitor and preparation pharmaceutical composition, and application thereof
IL297201A (en) * 2016-03-01 2022-12-01 Corcept Therapeutics Inc Use of glucocorticoid receptor modulators to increase the activity of checkpoint inhibitors
US10150754B2 (en) * 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CA3045855A1 (fr) 2016-11-10 2018-05-17 Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. Compose macrocyclique azote, son procede de preparation, sa composition pharmaceutique et son application
CN106905347B (zh) * 2017-04-18 2019-04-16 四川大学 Brd4抑制剂及其在肿瘤治疗药物中的应用
WO2019080941A1 (fr) * 2017-10-27 2019-05-02 Jacobio-Beta Pharmaceuticals Co., Ltd. Nouveaux composés tricycliques
AU2019295983B2 (en) 2018-06-25 2021-09-30 Jacobio Pharmaceuticals Co., Ltd. Tricyclic compounds
CN108840868B (zh) * 2018-08-01 2019-10-18 上海山的实业有限公司 具有抗肿瘤活性的吲哚并吡啶酮类化合物的制备方法及应用
WO2020132046A1 (fr) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Méthodes de traitement du cancer comprenant l'administration d'un modulateur du récepteur des glucocorticoïdes et d'un agent chimiothérapeutique anticancéreux
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020200284A1 (fr) * 2019-04-04 2020-10-08 上海华汇拓医药科技有限公司 Procédé de préparation de composé tricyclique et son utilisation dans le domaine de la médecine
CN110003204B (zh) * 2019-04-30 2020-08-11 上海勋和医药科技有限公司 一种bet蛋白抑制剂、其制备方法及用途
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
CN120623106A (zh) 2019-09-30 2025-09-12 协和麒麟株式会社 Bet降解剂
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
WO2022156757A1 (fr) * 2021-01-22 2022-07-28 Jingrui Biopharma Co., Ltd. Composés tricycliques en tant qu'agents anticancéreux
MX2023009858A (es) * 2021-02-25 2023-09-12 Impact Biomedicines Inc Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis.
US12016847B2 (en) * 2021-03-12 2024-06-25 Bristol-Myers Squibb Company Methods of treating prostate cancer
EP4334286A4 (fr) * 2021-05-06 2025-03-19 Raziel Therapeutics Ltd. Dérivé de carbazole cristallin
WO2024099441A1 (fr) * 2022-11-11 2024-05-16 Jingrui Biopharma (Shandong) Co., Ltd. Dégradeur de protéine à bromodomaines et domaine extra-terminal (bet)

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3427093A (en) * 1992-01-15 1993-08-03 E.I. Du Pont De Nemours And Company Bridged heterocyclic fungicides
EP1677786A1 (fr) 2003-10-18 2006-07-12 Bayer HealthCare AG Derives de 2-(phenylmethyl)thio-4-phenyl-4h-1,2,4-triazole substitues en 5 et composes associes utilises en tant que gaba-agonistes dans le traitement de l'incontinence urinaire et des maladies associees
WO2005051318A2 (fr) * 2003-11-24 2005-06-09 Viropharma Incorporated Composes, compositions et procedes pour le traitement et la prophylaxie d'infections de l'hepatite c virale et de maladies associees
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US8450351B2 (en) 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
WO2008036642A2 (fr) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinohétérocycles en tant que modulateurs d'indoléamine 2,3-dioxygénase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP1987839A1 (fr) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2044949A1 (fr) 2007-10-05 2009-04-08 Immutep Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
FR2927330B1 (fr) 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP3255060A1 (fr) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
EP2370407B1 (fr) * 2008-12-19 2014-06-18 Bristol-Myers Squibb Company Carbazoles et carbolines en tant qu'inhibiteurs de kinase
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
EP2493862B1 (fr) 2009-10-28 2016-10-05 Newlink Genetics Corporation Dérivés imidazole comme inhibiteurs de l'ido
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
JP5575274B2 (ja) 2010-02-26 2014-08-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン
EP2542256B1 (fr) 2010-03-04 2019-05-22 MacroGenics, Inc. Anticorps réagissant avec b7-h3, fragments immunologiquement actifs associés et utilisations associées
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
TWI503323B (zh) * 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之ｐｂｋ抑制劑
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
WO2011159760A1 (fr) 2010-06-16 2011-12-22 Vitae Pharmaceuticals, Inc. Hétérocycles à 5, 6 et 7 chaînons substitués, médicaments contenant ces composés et leur utilisation
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
TW201500358A (zh) * 2010-12-16 2015-01-01 赫夫門羅氏藥廠股份有限公司 三環ｐｉ３ｋ抑制劑化合物及其使用方法
US8580399B2 (en) * 2011-04-08 2013-11-12 Universal Display Corporation Substituted oligoazacarbazoles for light emitting diodes
NO2694640T3 (fr) 2011-04-15 2018-03-17
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
WO2013046635A1 (fr) * 2011-09-28 2013-04-04 出光興産株式会社 Substance pour élément électroluminescent organique, et élément électroluminescent organique produit en utilisant celle-ci
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2961747B1 (fr) * 2013-02-27 2017-11-15 Bristol-Myers Squibb Company Composés de carbazole utiles en tant qu'inhibiteurs de bromodomaine
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
EP2970312B1 (fr) * 2013-03-11 2017-11-15 The Regents of The University of Michigan Inhibiteurs de bromodomaines bet et méthodes thérapeutiques les utilisant
KR102457145B1 (ko) * 2013-12-24 2022-10-19 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 트리시클릭 화합물

Also Published As

Publication number Publication date
CN108558871A (zh) 2018-09-21
EP3087071A1 (fr) 2016-11-02
CY1121076T1 (el) 2019-12-11
DK3466949T3 (da) 2021-03-15
HUE054183T2 (hu) 2021-08-30
JP6675501B2 (ja) 2020-04-01
AU2014369982A1 (en) 2016-08-04
ES2857848T3 (es) 2021-09-29
KR20160095168A (ko) 2016-08-10
JP6466456B2 (ja) 2019-02-06
PT3087071T (pt) 2018-11-29
PT3466949T (pt) 2021-02-25
MY176489A (en) 2020-08-12
CN108558871B (zh) 2022-02-18
SG11201605097SA (en) 2016-07-28
EA032469B1 (ru) 2019-05-31
HRP20210212T1 (hr) 2021-07-09
DK3087071T3 (da) 2019-01-02
EP3466949A1 (fr) 2019-04-10
PL3087071T3 (pl) 2019-03-29
HUE041719T2 (hu) 2019-05-28
IL246359A0 (en) 2016-08-31
HRP20181849T1 (hr) 2018-12-28
CY1124061T1 (el) 2022-05-27
EA201990240A1 (ru) 2019-06-28
BR112016013744B1 (pt) 2022-08-30
CN106029663B (zh) 2018-06-01
CA2934953A1 (fr) 2015-07-02
LT3466949T (lt) 2021-03-25
PL3466949T3 (pl) 2021-05-31
EA201691070A1 (ru) 2016-11-30
NZ722326A (en) 2019-09-27
PE20160844A1 (es) 2016-09-03
RS58014B1 (sr) 2019-02-28
AU2014369982B2 (en) 2019-04-18
UY35916A (es) 2015-06-30
JP2019070014A (ja) 2019-05-09
SI3466949T1 (sl) 2021-03-31
SMT202100165T1 (it) 2021-05-07
KR102457145B1 (ko) 2022-10-19
WO2015100282A1 (fr) 2015-07-02
LT3087071T (lt) 2018-11-12
MX2016007928A (es) 2016-08-03
TWI726544B (zh) 2021-05-01
RS61479B1 (sr) 2021-03-31
JP2017505762A (ja) 2017-02-23
SI3087071T1 (sl) 2018-11-30
TWI736517B (zh) 2021-08-21
CN106029663A (zh) 2016-10-12
SMT201800643T1 (it) 2019-01-11
TN2016000238A1 (en) 2017-10-06
HRP20210212T8 (hr) 2021-08-20
AR123996A2 (es) 2023-02-01
CA2934953C (fr) 2022-09-20
EP3466949B1 (fr) 2020-12-23
MA39211B1 (fr) 2019-01-31
TW202028203A (zh) 2020-08-01
BR112016013744A2 (fr) 2017-10-03
TW201609725A (zh) 2016-03-16
CL2016001629A1 (es) 2017-02-17
AR099379A1 (es) 2016-07-20
ES2698998T3 (es) 2019-02-06
IL246359B (en) 2020-04-30
EP3087071B1 (fr) 2018-09-05
PH12016500953A1 (en) 2016-06-27
MX369491B (es) 2019-11-11
US20160318928A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MA42109B1 (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
CA2871471C (fr) Inhibiteurs d'adn pk
IN2015DN01156A (fr)
MA35920B1 (fr) Composés destinés au traitement de l'amyotrophie spinale
MA39193A1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
PH12015502658A1 (en) 3,4-dihydroisoquinolin-2 (1h)-yl compounds
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA35638B1 (fr) 2-thiopyrimidinones
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA40281B1 (fr) Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA38925B1 (fr) Dérivés de phénylalanine substitués
CL2011000865A1 (es) Compuestos derivados de isoquinolinona; composicion farmaceutica que los comprende; y uso del compuesto para tratar enfermedades tales como psicosis, esquizofrenia, alzheimer entre otras.
MA32061B1 (fr) Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments
UA119446C2 (uk) 1,2,4-ТРИАЗОЛО[4,3-а]ПІРИДИНОВІ СПОЛУКИ ТА ЇХ ЗАСТОСУВАННЯ ЯК ПОЗИТИВНИХ АЛОСТЕРИЧНИХ МОДУЛЯТОРІВ РЕЦЕПТОРІВ MGLUR2
MX2009010225A (es) Nuevos compuestos 707 y sus usos.
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA39533B1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MA38636A1 (fr) Composés de 3,4-dihydroisoquinoléin-2(1h)-yle
MA38411B1 (fr) Inhibiteurs de cdc7